0001493152-22-028693.txt : 20221122 0001493152-22-028693.hdr.sgml : 20221122 20221018205027 ACCESSION NUMBER: 0001493152-22-028693 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20221018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: SUITE 100 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: SUITE 100 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 CORRESP 1 filename1.htm

GT Biopharma, Inc.

8000 Marina Blvd, Suite 100

Brisbane, CA 94005

October 18, 2022

Via EDGAR Submission

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Mr. Jimmy McNamara

Re:	GT Biopharma, Inc.
	Registration Statement on Form S-3
	Filed on October 13, 2022
	File No. 333-267870

Dear Mr. McNamara:

Pursuant to Rules 460 and 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), GT Biopharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 5:00 p.m., Eastern Time, on Thursday, October 20, 2022, or as soon as practicable thereafter. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Baker & McKenzie LLP, by calling Roger W. Bivans at (214) 978-3095.

Thank you for your assistance with this matter.

	Very Truly Yours,

	By:	/s/ Manu Ohri
	Name:	Manu Ohri
	Title:	Chief Financial Officer

cc: Roger W. Bivans, Baker & McKenzie LLP